Natera Partners with Susan G. Komen to Advance Breast Cancer Detection and Awareness — Natera, Inc.

Event summary

Natera and Susan G. Komen announced a national partnership on August 28, 2026, to accelerate breast cancer awareness and education.
Natera’s Signatera™ MRD test, supported by 185 peer-reviewed publications, will be promoted through the partnership.
Natera will serve as the 2026 Premier National Series Sponsor of Susan G. Komen’s Race for the Cure® and MORE THAN PINK Walk® events.
The partnership aims to increase understanding of minimal residual disease (MRD) and improve breast cancer outcomes.

The big picture

Natera’s partnership with Susan G. Komen aligns with its strategy to advance precision medicine in oncology. By leveraging Komen’s extensive network and advocacy efforts, Natera aims to enhance the understanding and adoption of its MRD testing technology. This collaboration comes at a time when breast cancer remains a significant global health challenge, with high diagnosis rates and mortality. The partnership could position Natera as a key player in the fight against breast cancer, potentially driving both clinical and commercial growth.

What we're watching

Clinical Validation: How the growing body of evidence for Natera’s Signatera™ MRD test will influence its adoption in breast cancer treatment.
Market Expansion: Whether this partnership will help Natera expand its reach in the oncology market beyond breast cancer.
Awareness Impact: The pace at which the partnership will raise awareness of MRD testing and its potential to personalize breast cancer care.